阿替洛尔

{{Drugbox
| Watchedfields = changed
| verifiedrevid = 458476745
| IUPAC_name = (RS)-2-{4-[2-Hydroxy-3-(propan-2-ylamino)propoxy]phenyl}acetamide
| image = Atenolol.svg
| width = 200
| image2 = Atenolol_3d_structure.png
| width2 = 200
| drug_name = Atenolol

| tradename = Tenormin
| Drugs.com =
| MedlinePlus = a684031
| licence_US = Atenolol
| pregnancy_AU = C
| pregnancy_US = D
| legal_status = Rx-only
| routes_of_administration = Oral or IV

| bioavailability = 40-50%
| protein_bound = 6-16%
| metabolism = Hepatic <10%
| elimination_half-life = 6-7 hours
| excretion = Renal
Lactic (In lactiferous females)

| CAS_number_Ref =
| CAS_number = 29122-68-7
| ATC_prefix = C07
| ATC_suffix = AB03
| PubChem = 2249
| IUPHAR_ligand = 548
| DrugBank_Ref =
| DrugBank = DB00335
| ChemSpiderID_Ref =
| ChemSpiderID = 2162
| UNII_Ref =
| UNII = 50VV3VW0TI
| KEGG_Ref =
| KEGG = D00235
| ChEBI_Ref =
| ChEBI = 2904
| ChEMBL_Ref =
| ChEMBL = 24

| C=14 | H=22 | N=2 | O=3
| smiles = O=C(N)Cc1ccc(OCC(O)CNC(C)C)cc1
| InChI = 1/C14H22N2O3/c1-10(2)16-8-12(17)9-19-13-5-3-11(4-6-13)7-14(15)18/h3-6,10,12,16-17H,7-9H2,1-2H3,(H2,15,18)
| InChIKey = METKIMKYRPQLGS-UHFFFAOYAT
| StdInChI_Ref =
| StdInChI = 1S/C14H22N2O3/c1-10(2)16-8-12(17)9-19-13-5-3-11(4-6-13)7-14(15)18/h3-6,10,12,16-17H,7-9H2,1-2H3,(H2,15,18)
| StdInChIKey_Ref =
| StdInChIKey = METKIMKYRPQLGS-UHFFFAOYSA-N
}}

阿替洛尔（）是一种选择性的拮抗剂，β-受体阻滞药的一种，用于治疗心血管疾病。在1976年，阿替洛尔被研发出来替代普萘洛尔作为治疗高血壓的药物，能降低心脏的活性。但与普萘洛尔不同，阿替洛尔不经过血脑屏障，从而避免各种对中樞神經系統的副作用。

註釋
參考文獻
*K.Viveksarathi et al.,Formulation Development and In-Vitro Evaluation of Gastroretentive Floating tablets of Atenolol. Journal of Pharmaceutical Sciences & Research;2011, Vol.3(12),p1632. http://www.jpsr.pharmainfo.in/Documents/Volumes/vol3Issue12/jpsr%2003111207.pdf

外部链接
*